

C

w

w

w



2 FINANCIAL HIGHLIGHTS

2.1 Principal Financial Data and Indicators

| | | For the year ended December 31, | |
|---|---|------------------------------------|----------------|
| | | 2024 | 2023 |
| | | (RMB'000) | (B'000) |
| | | 1,654,289 | 1,596,266 |
| | | 68,099 | 99,182 |
| | | 17,702 | 12,250 |
| | | 50,398 | 86,932 |
| | C | 65,610 | 85,948 |
| - | | -15,212 | 984 |
| | | As at | A |
| | | December 31, | 31, |
| | | 2024 | 2023 |
| | | (RMB'000) | (B'000) |
| | | 3,004,953 | 3,047,687 |
| | | 1,661,651 | 1,639,481 |
| | | 1,343,302 | 1,408,206 |
| | C | 1,223,013 | 1,265,065 |
| - | | 120,289 | 143,141 |
| | | For the year ended December 31, | |
| | | 2024 | 2023 |
| | | (RMB'000) | (B'000) |
| | | 99,639 | 265,033 |
| | | -172,055 | -215,017 |
| | | -76,917 | 96,107 |
| | | <u>-149,491</u> | <u>146,127</u> |

w, B

☒

Elderly Healthcare Business

C

"(老齡健康)"
(銀發經濟)

w

w. ☒

w

A D 31, 2024, ☒

2,580

B461.9

2024,

30.4%

☒

w

w

☒

C

w

C

C

☒

w

w

w

3.2 Business Highlights

2024, ☒

(

5

164

),

☒

85

25

C

),

6

W

W

:

| | For the year ended | |
|---|---------------------------|------------------|
| | December 31, | |
| | 2024 | 2023 |
| | (RMB'000) | (B'000) |
| Revenue from operating owned hospitals | 1,517,773 | 1,485,161 |

2023, w w B1,582.1 , B 2.9% w w
 , D
 B64.3 ,
 B 12.0 2023,
 B 4.1% (2023: 3.4%).

w w B ,
 :
 :

**For the year ended
 December 31,
 2024 2023
 (RMB'000) (B'000)**

**Billing Revenue from psychiatric
 healthcare business**

| | | |
|---|------------------|-----------|
| C | 1,107,269 | 1,095,073 |
| ☒ | 745,959 | 736,163 |
| ☒ | 361,310 | 358,910 |

**Billing Revenue from elderly
 healthcare business**

| | | |
|---|----------------|---------|
| C | 474,785 | 442,333 |
| ☒ | 379,458 | 371,757 |
| ☒ | 95,327 | 70,576 |

D , B ☒ , w
 B1,582.1 , B44.6
 w 2023, B
 , ☒ , w
 , D
 C , w
 , D
 ☒ , B . D ,
 w 2023, w 6.3%
 - w .
 w B ☒ , w
 , w :

| | For the year ended December 31, | |
|--|------------------------------------|-----------------------|
| | 2024 | 2023 |
| Total treatment and general healthcare services revenue (RMB'000) | <u>889,154</u> | <u>886,642</u> |
| Total pharmaceutical sales revenue (RMB'000) | <u>218,115</u> | <u>208,431</u> |
| D w 2023, | B933.7 | B , |
| | 5.6% | 0.4% |
| | w | - |
| | C | w |
| | , C | 2023. |
| | B | 5.0% |
| | B | 84.3% (2023: 84.9%) |
| D w 2023, | B173.5 | B , |
| | w | 12.6% |
| | B | 20.1% |
| | 15.7% (2023: 15.1%) | 4.9% |
| D | , | B |
| | w, | B |
| | w 2023, w | B |
| | 80.3% (2023: 81.0%), | B |
| | w 2023, | 19.7% (2023: 19.0%) |
| | B | .5 (.)12 ()0 |
| | 9.6% (2023: 9.5%), | B |
| | B | B |
| | 72.8%). | 74.0% (2023: |

Elderly healthcare business

| | | For the year ended December 31, | |
|-------------------|-----|------------------------------------|-----------|
| | | 2024 | 2023 |
| Inpatients | | 2,580 | 2,540 |
| | - | 944,280 | 927,100 |
| | (%) | 96.1 | 79.3025 w |

D , B
w 2023, B439.7 , 12.9%
- - 23.4%
, C
B
92.6% (2023: 88.1%) B

D , B
w 2023, B35.1 , 33.5%
16.3% 20.5%

B C
B 7.4% (2023: 11.9%)

D ,
w, B
10.3% w 2023, w
B
76.2% (2023: 74.2%), B
23.8% (2023: 25.8%) B 1.1% w 2023,
B
21.3% (2023: 21.7%), B
55.5% (2023: 56.1%).

C , w
, - -
w : w , w

| | For the year ended December 31, | |
|---|------------------------------------|------------------|
| | 2024 | 2023 |
| | (RMB'000) | (B'000) |
| D | 340,120 | 365,896 |
| D | 464,874 | 435,287 |
| C | 127,032 | 121,071 |
| C | 68,571 | 65,183 |
| | 16,112 | 21,092 |
| | 108,708 | 99,391 |
| Cost of revenue of owned hospitals | 1,125,417 | 1,107,920 |

D
 2023. w B1,125.4 , w 1.6% w
 : () 7.0%
 w 2023; () 6.8%
 2023. - w 4.9% ; () w
 , w 30.2% (2023:
 33.0%).
 w 41.3% (2023: 39.3%).
 - w w 11.3% (2023:
 10.9%).

4.1.3 Tax and Surcharge

D (2023: B6.5), B12.3
w B4.9), w 2023. -

4.1.4 Selling Expenses

D (2023: B17.1), B10.0
w B17.1), 6.0.7% (2023:1.2%).

| | | For the year ended December 31, | |
|--------------|---|------------------------------------|---------------|
| | | 2024 | 2023 |
| | | (RMB'000) | (B'000) |
| C | | 25,088 | 20,552 |
| D | w | 9,827 | 8,436 |
| C | | 1,604 | 3,427 |
| | | — | 51 |
| Total | | 36,519 | 32,466 |

D B36.5 (2023: B32.5), 12.5%
w 2023.
w 2.4% (2023: 2.2%),
C
C D .

4.1.7 Finance Expenses – Net

, w
w :

| | | For the year ended December 31, | |
|-------------------------------|---|------------------------------------|---------------|
| | | 2024 | 2023 |
| | | (RMB'000) | (B'000) |
| | / | -3,123 | -5,266 |
| B | w | 157 | -4 |
| | | 33,143 | 30,180 |
| | | 8,458 | 9,755 |
| | | 7,900 | 5,694 |
| | | 1,058 | 1,093 |
| Finance expenses – net | | 47,593 | 41,452 |

D B47.6 , B6.1 w 2023,
w B5.2 w 2023.

4.1.8 Investment Gains/Losses

/

-

.

4.1.11 Non-Operating Income and Non-Operating Expenses

| | For the year ended December 31, | |
|-------------------------------|------------------------------------|----------------------|
| | 2024 (RMB'000) | 2023 (B'000) |
| ☒ | 86 | 566 |
| D | 47 | 5,975 |
| - | <u>1,396</u> | <u>3,004</u> |
| Non-operating income | <u>1,529</u> | <u>9,545</u> |
| | 1,117 | 291 |
| D | 2,698 | 4,494 |
| - | <u>2,669</u> | <u>3,830</u> |
| | <u>2,299</u> | <u>3,201</u> |
| Non-operating expenses | <u>8,783</u> | <u>11,816</u> |
| D | ☒ | |
| B1.5 | | B8.0 |
| | | w 2023, |

4.2 Financial Position

4.2.1 Inventory

A D 31, 2024, B50.6 ()
D 31, 2023: B60.6),

4.2.2 Accounts Receivable

A D 31, 2024, B571.8
(D 31, 2023: B420.4),
36.0% w D 31, 2023,

D w 54 (2023: 46).

4.2.3 Other Receivables and Prepayments

A D 31, 2024, B96.1
(D 31, 2023: B79.5).

4.2.4 Long-term Equity Investments

A D 31, 2024, -
B99.4 (D 31, 2023: B139.1),
B21.6 C ..
B10.8 C ..

4.2.5 Other Non-current Financial Assets

A D 31, 2024, -
B36.8 (D 31, 2023: B65.1),
& C & (重慶金浦醫療健康服務
產業股權投資基金合夥企業(有限合夥)).

4.2.6 Fixed Assets

A D 31, 2024, B889.5
(D 31, 2023: B794.9), w
B115.9 C

4.2.7 Construction in Progress

A D 31, 2024, 31, 2023: w
B185.2 (D B187.0). w

4.2.8 Right-of-use Assets

A D 31, 2024, - - B161.8 (- -
D 31, 2023: B189.1),
B36.1 .

4.2.9 Intangible Assets

A D 31, 2024, B291.5 (-
D 31, 2023: B320.3),
B24.9 .

4.2.10 Goodwill

A D 31, 2024, w B114.2 (D
31, 2023: B119.9), w
B5.7 .

4.2.11 Long-term Prepaid Expenses

A D 31, 2024, - B150.4
(D 31, 2023: B175.9), w
B11.6
B36.9 .

4.2.12 Deferred Tax Assets

A D 31, 2024, B56.2 (-
D 31, 2023: B45.1),
B6.5 .

4.2.13

4.2.14 Receipts in Advance and Contract Liabilities

A D 31, 2024,
B21.3 (D 31, 2023: B26.6).

4.2.15 Other Payables

A D 31, 2024, B81.3 ()
D 31, 2023: B150.3),
w w
, ,
C .

4.3 Liquidity and Capital Resources

w w
⊠ :

| For the year ended December 31, | |
|--|-----------------|
| 2024 | 2023 |
| (RMB'000) | (B'000) |
| 99,639 | 265,033 |
| -172,055 | -215,017 |
| -76,917 | 96,107 |
| -149,491 | 146,127 |

4.3.1 Net Cash Generated from Operating Activities

D ,
B99.6 , B50.4 ,
B43.0 ,
B154.8 ,
62.4% w
2023, B134.9
D 31, 2024 w D 31, 2023. C
w w B177.6 .

4.3.2 Net Cash Used in Investing Activities

D ,
B172.1 , B192.2
, , ,
, , C
, .

4.3.3 Net Cash Generated from Financing Activities

D ,
B-76.9 .

4.3.4 Significant Investment, Acquisition and Disposal

,
 A , w
 B

4.4 Indebtedness

4.4.1 Bank Borrowings

A D 31, 2024, w
 B946.2 (D 31, 2023: B864.7),
 w B448.5 w B367.0

4.4.2 Contingent Liabilities

A D 31, 2024,
 w

4.4.3 Asset Pledge

D , ,
 w D .
 826751, . 826750, (2016) D .
 . 0010144, (2016) . 0010142,
 (2021) . 0081628, (2015) . 1-11836,
 (2015) . 1-11833 B w
 - , (2017) C C . 0018361 CBC
 B - . A D 31, 2024,
 w B430.7 .
 . 0068897 w (2020)
 A D 31, 2024, B C C w
 B115.6 . C - .
 (2022) . 00025C 2.9 (2)12.9

4.4.4 Lease Liabilities

As at 31, 2024, the carrying amount of lease liabilities was B151.3 million. As at 31, 2023, the carrying amount of lease liabilities was B26.7 million.

4.4.5 Financial Instruments

The carrying amount of financial instruments is as follows:

| Category | 31, 2024 (B million) | 31, 2023 (B million) |
|-----------------------|----------------------|----------------------|
| Financial assets | 1,511.3 | 1,511.3 |
| Financial liabilities | 1,511.3 | 1,511.3 |

4.4.6 Exposure to Fluctuation in Exchange Rates

The Group's operations are primarily conducted in the United States. The Group's assets and liabilities are denominated in US dollars. The Group's revenue is primarily denominated in US dollars. The Group's expenses are primarily denominated in US dollars. The Group's net income is primarily denominated in US dollars. The Group's net assets are primarily denominated in US dollars. The Group's net liabilities are primarily denominated in US dollars. The Group's net equity is primarily denominated in US dollars. The Group's net debt is primarily denominated in US dollars. The Group's net cash and equivalents are primarily denominated in US dollars. The Group's net receivables are primarily denominated in US dollars. The Group's net payables are primarily denominated in US dollars. The Group's net assets and liabilities are primarily denominated in US dollars. The Group's net equity and debt are primarily denominated in US dollars. The Group's net cash and equivalents are primarily denominated in US dollars. The Group's net receivables are primarily denominated in US dollars. The Group's net payables are primarily denominated in US dollars.

4.4.7 Gearing Ratio

The Group's gearing ratio is as follows:

| Year | Gearing Ratio (%) |
|----------|-------------------|
| 31, 2024 | 55.3% |
| 31, 2023 | 53.8% |

4.4.8 Employees and Remuneration Policy

The Group's employees and remuneration policy is as follows:

| Year | Number of Employees | Total Remuneration (B million) |
|----------|---------------------|--------------------------------|
| 31, 2024 | 4,869 | 1,511.3 |
| 31, 2023 | 4,765 | 1,511.3 |

2018, the Company (Equity Incentive Scheme), which was considered and approved at the annual general meeting of the Company for the year 2017 convened on June 13, 2018. In order to meet the requirement of ascertained share capital for the Company's share listing application in the future, the Board of the Company considered and approved the resolutions regarding, among others, further amendments to the Equity Incentive Scheme to cancel the performance assessment requirements and the Company's obligation to repurchase the locked incentive shares under the Equity Incentive Scheme, at the Board meeting held on June 24, 2021. Unless otherwise specified, capitalized terms used hereinafter shall have the same meanings as those defined in the announcement of the Company dated May 29, 2018, the supplementary circular dated May 30, 2018, the circular dated May 14, 2021, the announcement dated June 18, 2021 and the announcement dated June 25, 2021.

Under the Equity Incentive Scheme, participants of the first actual grant comprised a total of 165 persons, with 1,818,529 incentive shares being granted. Participants of the second phase of the actual grant comprised a total of 23 persons, with 180,516 incentive shares being granted. Participants (including connected persons) of the third phase of the actual grant comprised a total of 13 persons, with 540,229 incentive shares being granted. As of the date of this announcement, a total of 8 participants exited, corresponding to a total of 79,274 incentive shares. As of the date of this announcement, participants of the actual grant under the Equity Incentive Scheme comprised 193 persons, and all 2,460,000 incentive shares proposed to be granted had been granted. The incentive shares granted accounted for 3.2976% of the total issued share capital of the Company as of the date of this announcement, and were unlocked at one time after 48 months from the date of grant at the grant price of RMB10.47 per share.

As all 2,460,000 incentive shares proposed to be granted under the Equity Incentive Scheme had been granted before June 18, 2021, the number of awards to be granted separately at the beginning and the end of the Reporting Period with the authorization under the Equity Incentive Scheme was nil. Therefore, there were no shares available for issuance under the Equity Incentive Scheme as at the date of this announcement.

4.4.8.2

Aw

,
w C w , , C
A A w , C Aw
, w w C 2023
w , C 27, 2023.
2023 C 27, 2023, A 8,
2024, A 23, 2024 18, 2024. 12,
Aw
w C Aw w w
Aw Aw w w
- C ,
C , C 5%
(Aw
(3,730,015) w Aw C w
w w . w
w , B / ,
w - w
Aw w
Aw (36 ,
w 364,100 w) (36
) 36
, w 616,000 .
(52 , w 335,000 w . A
7
75,000 w . A , ,
Aw 101
, 1,240,100 w . w
C 1.71%
C
C 8, 2023
23, 2024 18, 2024. 27, 2023, A 12, 2024, A

5 SIGNIFICANT EVENTS

5.1 Proposed Final Dividend

| | B | D | | D | . B |
|---|------|--------|---------------|--------|-------------------|
| C | | | 2024 (| | , |
| | | | 72,670,000 | | w |
| | B3 (| |) 10 | C | , w |
| | | | B21,801,000 (| | 33.2% |
| | | |) | | |
| | D | 2024 | (| | 49.8% |
| | | | B32,701,000, | | |
| | | | C | | |
| | B, | |) | D | w |
| | | B | | D | |
| | | | | D | D |
| B | C | | D | B | , |
| | 6 (| 0.06 8 | .0 8 | 0.06 8 | .0 8 |
| | | | | CA | .11) 0.025 w 0 (|

C ()

A D 31, 2024, ☒

7 REVIEW OF ANNUAL RESULTS

A C w D , . ☒
D , . C . A C) . , -
(C A) . ☒ C
C A).

A C w ☒ ,
D 31, 2024
w C .

8 COMPLIANCE WITH CG CODE

D w ☒ C . , C

9 COMPLIANCE WITH THE MODEL CODE

C , C C
D D , D C , D . C
C w C

10 EVENTS AFTER THE REPORTING PERIOD

w ☒

11 AUDITORS AND WORKING SCOPE

☒ 2024, w
w C A B
BD , w w

☒ ,

W

, ,

,

, , ,
w w
) , (w
, , w
, w
.
w , () ,
w w
,
w

() . 18 A

☒ B A

D 6, 2024,
.18 A
2024 . 24,

B (C
Interpretation No. 18).

w

. 18

w

w . B C B . 13 C A
C B

- C D w C

w

C .

12.1.1.2 C

D , w C

12.2 Annual Consolidated Financial Information

C A B ☒ w :

12.2.1 Annual Consolidated Income Statement

(A B w)

| Items | For the year ended December 31, | |
|--------------------------------|------------------------------------|---------------|
| | 2024 | 2023 |
| I. Total revenue | 1,654,289,413 | 1,596,265,532 |
| : | 1,654,289,413 | 1,596,265,532 |
| | - | |
| | - | |
| | - | |
| | 1,549,653,899 | 1,495,651,128 |
| II. Total cost of sales | 1,549,653,899 | 1,495,651,128 |
| : C | 1,215,885,486 | 1,185,129,955 |
| | - | |
| | - | |
| | - | |
| | - | |
| | - | |
| | - | |
| | 12,336,886 | 6,474,904 |
| | 9,972,500 | 17,102,355 |
| ⊗ | 227,346,205 | 213,025,707 |
| | 36,519,661 | 32,466,196 |
| | 47,593,160 | 41,452,011 |
| : | 41,601,182 | 39,936,115 |
| | 3,122,806 | 5,265,571 |
| A : | 13,253,819 | 15,976,715 |
| (w -) | 754,877 | -6,067,197 |
| : | -1,089,495 | -6,465,279 |
| D | - | |
| | - | |
| (w -) | - | |
| ⊗ | - | |
| (w -) | - | |
| ⊗ | - | |
| (w -) | -269,736 | 214,405 |
| C | - | |
| (w -) | -26,454,998 | -9,354,736 |
| A | - | |
| (w -) | -16,495,930 | |
| ⊗ | - | |
| (w -) | -69,932 | 68,089 |
| | 68,089 | |

| Items | For the year ended December 31, | |
|--|------------------------------------|-----------------------------|
| | 2024 | 2023 |
| - | - | |
| | <u> </u> | <u> </u> |
| VII. Total comprehensive income | 50,397,711 | 86,931,608 |
| A | 65,610,189 | 85,947,807 |
| A | -15,212,477 | 983,801 |
| | <u> </u> | <u> </u> |
| VIII. Earnings per share: | | |
| () B (B) | 0.88 | 1.15 |
| () D (B) | 0.88 | 1.15 |
| | <u> </u> | <u> </u> |

12.2.2 Annual Consolidated Balance Sheets

| (A | B | w |) |
|------------------------|--------------|---|------|
| ASSETS | December 31, | D | 31, |
| | 2024 | | 2023 |
| Current assets: | | | |
| C | | | |

| ASSETS | December 31, 2024 | D 31, 2023 |
|---|------------------------------|-----------------------------|
| Non-current assets: | | |
| Ⓢ | - | |
| D | - | |
| | - | |
| - | 14,000,000 | 14,000,000 |
| - | 99,413,985 | 139,071,987 |
| | - | |
| - | 36,755,116 | 65,099,055 |
| | - | |
| | 889,544,442 | 794,856,343 |
| C | 185,164,227 | 186,980,241 |
| | - | |
| | - | |
| - - | 161,821,445 | 189,054,507 |
| | 291,535,792 | 320,321,705 |
| D | - | |
| Ⓢ w | 114,158,434 | 119,909,089 |
| - | 150,407,031 | 175,910,626 |
| D | 56,197,545 | 45,146,271 |
| - | 11,233,664 | 9,689,211 |
| | <hr/> | <hr/> |
| Total non-current assets | <u>2,010,231,682</u> | <u>2,060,039,035</u> |
| | | |
| TOTAL ASSETS | <u>3,004,953,161</u> | <u>3,047,686,607</u> |
| | | |
| LIABILITIES AND SHAREHOLDERS' EQUITY | December 31, 2024 | D 31, 2023 |
| Current liabilities: | | |
| - w | 91,000,000 | 127,001,700 |
| B w | - | - |
| | - | |
| | 14,000,000 | 12,400,000 |
| D | - | |
| | - | 1,545,021 |
| A | 131,936,380 | 110,060,008 |
| | 21,319,198 | 26,563,603 |
| C | 49,771 | |
| | - | |

**LIABILITIES AND
SHAREHOLDERS' EQUITY**

| | | December 31, 2024 | D 31, 2023 |
|--------------------------------------|---|-----------------------------|-----------------------------|
| | | - | |
| | | - | |
| | w | - | |
| | | 85,747,297 | 84,324,006 |
| | | 39,128,084 | 38,553,746 |
| | | 81,287,433 | 150,270,576 |
| | | - | |
| | | - | |
| | | - | |
| - | w | 229,270,444 | 250,411,757 |
| | | 615,218 | |
| | | <hr/> | <hr/> |
| Total current liabilities | | <u>694,353,825</u> | <u>801,130,416</u> |
| Non-current liabilities: | | | |
| | | - | |
| - | w | 691,017,337 | 557,719,215 |
| B | | - | |
| : | | - | |
| | | - | |
| | | 151,300,063 | 163,239,533 |
| - | | 76,236,879 | 61,351,341 |
| - | | - | |
| | | - | |
| D | | 8,430,307 | 8,734,099 |
| D | | 40,313,059 | 47,306,056 |
| - | | - | |
| | | <hr/> | <hr/> |
| Total non-current liabilities | | <u>967,297,645</u> | <u>838,350,244</u> |
| Total liabilities | | <u>1,661,651,470</u> | <u>1,639,480,660</u> |

**LIABILITIES AND
SHAREHOLDERS' EQUITY**

| | December 31, 2024 | D | 31, 2023 |
|------------------------------|------------------------------|---|-------------|
| Shareholders' equity: | | | |
| | 72,670,000 | | 74,600,300 |
| : | - | | |
| : | - | | |
| : | - | | |
| C | 790,024,238 | | 852,695,602 |

| Items | For the year ended December 31, | |
|---|---------------------------------|-----------------------------|
| | 2024 | 2023 |
| C | <u>46,542,855</u> | <u>215,257,897</u> |
| Sub-total of cash inflows of operating activities | <u>1,434,048,253</u> | <u>1,778,973,721</u> |
| C | 536,137,779 | 534,160,766 |
| | - | |
| w | - | |
| C | - | |
| | - | |
| | - | |
| C | - | |
| C | - | |
| C | 642,555,983 | 588,242,659 |
| | 63,003,045 | 54,415,007 |
| C | <u>92,712,942</u> | <u>337,122,052</u> |
| Sub-total of cash outflows of operating activities | <u>1,334,409,749</u> | <u>1,513,940,484</u> |
| Net cash flows from operating activities | <u>99,638,504</u> | <u>265,033,237</u> |
| II. Cash flows from investing activities | | |
| C | 34,242,179 | 8,279,458 |
| C | - | - |
| | - | |
| | 1,844,120 | 2,924,937 |
| | 2,000,000 | - |
| C | - | 1,248,000 |
| Sub-total of cash inflows of investing activities | 38,086,299 | 12,452,395 |
| C | - | |
| | 192,178,989 | 179,732,394 |
| C | 17,020,000 | 2,447,873 |
| | - | |
| | - | 31,289,153 |
| C | 942,428 | 14,000,060 |
| Sub-total of cash outflows of investing activities | <u>210,141,417</u> | <u>227,469,480</u> |

| Items | For the year ended December 31, | |
|--|---------------------------------|---------------------|
| | 2024 | 2023 |
| Net cash flows from investing activities | <u>-172,055,118</u> | <u>-215,017,085</u> |
| III. Cash flows from financing activities | | |
| C | 7,210,500 | 2,999,500 |
| : C | | |
| - | 7,210,500 | 2,999,500 |
| C | 448,460,250 | 605,774,670 |
| C | 60,000,000 | 55,900,000 |
| Sub-total of cash inflows of financing activities | 515,670,750 | 664,674,170 |
| C | 367,013,827 | 357,677,873 |
| C | 74,654,124 | 357,677,873 |
| | | 357,677,873 |

12.2.4 Consolidated Statement of Changes in Shareholders' Equity

(A B w)

| Items | Other equity instruments | | | | Amount for the current period Equity attributable to owners of the parent company | | | | | | | | Non - controlling interests | Total owners' equity |
|-------|--------------------------|---------------------|--------------------|--------|--|-------------------|----------------------------------|--------------------|--------------------|-------------------------------|----------------------|---------------|-----------------------------------|----------------------------|
| | Share capital | Preferred shares | Perpetual bonds | Others | Capital reserve | Less: | | Special reserve | Surplus reserve | Provision for general risk | Retained earnings | Subtotal | | |
| | | | | | | Treasury stock | Other comprehensive income | | | | | | | |
| B | 74,600,300 | - | - | - | 852,695,602 | 12,587,012 | - | - | 38,399,577 | - | 311,956,229 | 1,265,064,696 | 143,141,251 | 1,408,205,947 |
| : C | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| C | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| B | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| B | 74,600,300 | - | - | - | 852,695,602 | 12,587,012 | - | - | 38,399,577 | - | 311,956,229 | 1,265,064,696 | 143,141,251 | 1,408,205,947 |
| / | -1,930,300 | - | - | - | -62,671,364 | 9,779,837 | - | - | - | - | 32,329,599 | -42,051,902 | -22,852,354 | -64,904,256 |
| () | - | - | - | - | - | - | - | - | - | - | 65,610,189 | 65,610,189 | -15,212,477 | 50,397,712 |
| () w | -1,930,300 | - | - | - | -27,437,605 | 9,779,837 | - | - | - | - | - | -39,147,741 | -4,748,360 | -43,896,101 |
| 1. C | - | - | - | - | -31,435,114 | 9,779,837 | - | - | - | - | - | -41,214,951 | -4,748,360 | -45,963,311 |
| 2. C | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. A | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| w | - | - | - | - | 3,997,510 | - | - | - | - | - | - | 3,997,510 | - | 3,997,510 |
| 4. | -1,930,300 | - | - | - | - | - | - | - | - | - | - | -1,930,300 | - | -1,930,300 |

| Items | Other equity instruments | | | | Amount for the current period Equity attributable to owners of the parent company | | | | | | | | Non - controlling interests | Total owners' equity |
|-----------|--------------------------|---------------------|--------------------|--------|--|-------------------|----------------------------------|--------------------|--------------------|-------------------------------|----------------------|---------------|-----------------------------------|----------------------------|
| | Share capital | Preferred shares | Perpetual bonds | Others | Capital reserve | Less: | | Special reserve | Surplus reserve | Provision for general risk | Retained earnings | Subtotal | | |
| | | | | | | Treasury stock | Other comprehensive income | | | | | | | |
| () D | - | - | - | - | - | - | - | - | - | - | -33,280,590 | -33,280,590 | -2,891,517 | -36,172,107 |
| 1. w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () | - | - | - | - | - | - | - | - | - | - | -33,280,590 | -33,280,590 | -2,891,517 | -36,172,107 |
| 4. w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () - w w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. C | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. C | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3. | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4. C - w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 5. C - w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 6. | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 1. w | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2. | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| () | - | - | - | - | -35,233,759 | - | - | - | - | - | - | -35,233,759 | - | -35,233,759 |
| B | 72,670,000 | - | - | - | 790,024,238 | 22,366,849 | - | - | 38,399,577 | - | 344,285,828 | 1,223,012,795 | 120,288,896 | 1,343,301,691 |

12.3 Notes to the Consolidated Annual Financial Information prepared in accordance with the China Accounting Standard for Business Enterprises

12.3.1 Accounts receivable

| | | w : | |
|--|--------------|----------------------------------|----------------------------------|
| | | December 31, 2024 RMB | D 31, 2023 B |
| | 1 | 576,106,514 | 425,833,221 |
| | 1-2 | 20,258,896 | 6,696,710 |
| | 2-3 | 4,413,822 | 4,480,033 |
| | 3 | 4,766,339 | 7,780,010 |
| | | <u>605,545,571</u> | <u>444,789,974</u> |
| | : | 33,732,614 | 24,348,904 |
| | Total | <u><u>571,812,957</u></u> | <u><u>420,441,070</u></u> |

| | | December 31, 2024 | | | | |
|---|--------------|----------------------------------|----------------------------|---------------------------------|--------------------------|----------------------------------|
| | | Balance of carrying amount | | Provision for bad debts | | Book value |
| | | Amount | Proportion (%) | Amount | Percent of provision (%) | |
| A | w | 12,375,106 | 2.0 | 12,337,791 | 99.7 | |
| | : | 12,375,106 | 2.0 | 12,337,791 | 99.7 | 37,315 |
| A | w | 593,170,465 | 98.0 | 21,394,823 | 3.6 | 571,775,642 |
| | : | <u>593,170,465</u> | <u>98.0</u> | <u>21,394,823</u> | <u>3.6</u> | <u>571,775,642</u> |
| | Total | <u><u>605,545,571</u></u> | <u><u>100.0</u></u> | <u><u>33,732,614</u></u> | <u><u>5.6</u></u> | <u><u>571,812,957</u></u> |

| | | D | | 31, 2023 | | | |
|---|---|--------------------|--------------|-------------------|------------|--------------------|--|
| | | B | | | | | |
| A | w | A | (%) | A | (%) | B | |
| | | 19,507,031 | 4.4 | 12,854,582 | 65.9 | 6,652,449 | |
| A | : | 19,507,031 | 4.4 | 12,854,582 | 65.9 | 6,652,449 | |
| A | w | 425,282,942 | 95.6 | 11,494,321 | 2.7 | 413,788,621 | |
| | : | 425,282,942 | 95.6 | 11,494,321 | 2.7 | 413,788,621 | |
| | | <u>444,789,973</u> | <u>100.0</u> | <u>24,348,903</u> | <u>5.5</u> | <u>420,441,070</u> | |

12.3.2 Accounts payable

| | | w : | |
|---|---|-----------------------------|--------------------|
| | | December 31, 2024 RMB | D 31, 2023 B |
| | | 127,861,415 | 107,790,035 |
| | w | 3,124,362 | 1,815,169 |
| w | | 751,142 | 85,740 |
| A | | <u>199,461</u> | <u>369,064</u> |
| | | <u>131,936,380</u> | <u>110,060,008</u> |

12.3.3 Revenue and cost of sales

| A | | For the year ended December 31, 2024 | | D 31, 2023 | | C | |
|---|--|---|----------------------|----------------------|--|---|----------------------|
| | | Revenue | Cost | | | | |
| | | 1,517,773,042 | 1,125,416,715 | 1,485,160,595 | | | 1,107,920,077 |
| | | <u>136,516,371</u> | <u>90,468,771</u> | 111,104,937 | | | <u>77,209,878</u> |
| | | <u>1,654,289,413</u> | <u>1,215,885,486</u> | <u>1,596,265,532</u> | | | <u>1,185,129,955</u> |

B w :

For the year ended December 31,
2024 **2023**

1,517,773,042 1,485,160,595
331,193,218 322,733,829
1,186,579,824 1,162,426,766

:

| | | | | |
|---|-----|-----|-------------------|---------------------------|
| D | | | | |
| D | | | () | w |
| | | | C (): | |
| | | | | For the year ended |
| | | | | December 31, |
| | | | | 2024 2023 |
| C | | () | 65,610,189 | 85,947,807 |
| | C | () | 74,278,583 | 74,600,300 |
| D | | | 0.88 | 1.15 |
| | : D | | 0.88 | 1.15 |
| | D | | | |

12.3.6 Income tax expenses

| | | | | |
|---|--|--|--------------------|---------------------------|
| | | | | |
| | | | | For the year ended |
| | | | | December 31, |
| | | | | 2024 2023 |
| C | | | 35,746,101 | 36,259,411 |
| D | | | -18,044,326 | -24,009,402 |
| | | | 17,701,775 | 12,250,009 |
| | | | | |
| | | | | |
| | | | | For the year ended |
| | | | | December 31, |
| | | | | 2024 2023 |
| | | | 68,099,487 | 99,181,617 |
| | | | | |
| | | | 13,700,455 | 19,960,640 |
| | | | -43,611 | -223,220 |
| A | | | 1,468,471 | -189,327 |
| | | | - | 3,879,078 |

| | | For the year ended December 31, | |
|---|---|------------------------------------|-------------------|
| | | 2024 | 2023 |
| | - | 6,053,711 | 2,133,262 |
| | , | -12,352,475 | -18,633,562 |
| | w | 16,429,655 | 13,333,667 |
| A | | -5,605,853 | -4,674,287 |
| | | -10,362 | -1,945,480 |
| | | <u>-1,938,216</u> | <u>-1,390,762</u> |
| | | <u>17,701,775</u> | <u>12,250,009</u> |

12.3.7 Dividend

| | | | | | | | |
|---|---------------|---|---|---|------------|-----------|-----------|
| | 28, 2025, | B | D | | D | 31, 2024, | |
| | B21,801,000 (|) | | C | | D | 31, 2024. |
| | 72,670,000 | | | | A | | |
| | | | | | | | |
| | A 28, 2024, | B | D | | | 30, 2024, | |
| | B10,900,500 (|) | | | | | |
| | | | | | 72,670,000 | | |
| | | | | | 2024 | | |
| | w | | | | | | |
| | 2024 | C | | | | 14, 2024. | |
| | 28, 2024, | B | D | | D | 31, 2023, | |
| | B22,380,090 (|) | | C | | D | 31, 2023. |
| | 74,600,300 | | | | | | 2023 |
| | w | | | | | | |
| C | | | | | | | 30, 2024. |

13 DEFINITIONS

| | | |
|---|-------|----------------------|
| A | C | 2024 |
| A | C | B |
| B | B | C ., . (北京怡寧醫院有限公司), |
| | 2015, | C w A 17, |
| | C | -w w |

B C

C C C., . (蒼南康寧醫院有限公司),
C w 15,
2012, C , w w

C C C., . (成都怡寧醫院有限公司)),
C w
29, 2010, C , -w w

C C C., . (長春康林心理醫院有限公司),
C w
16, 2016, C ,
-w w

C , C , (淳安康寧黃鋒醫院有限公司),
C w
A 16, 2020, C ,
-w w

C C., ., C,
w B
(C : 2120)

C C A C1

D () () C

D () () C , w
B1.00 , w
B w

D D C., . (洞口樂寧醫院有限公司),
C w 5,
2018, C , -w w

w C

() () B1.00
C , w
B

C ., (平陽康寧醫院有限公司),
 C w
 2, 2015, C , w w
 C C D
 A C3
 C C ., . (平陽長庚怡寧
 醫院有限公司), C w
 C w
 14, 2021, C , w w
 C C , C w ,
 A , C w ,
 D) 10 D B3 (31, 2024
 A
 D
 C ., . (衢州怡寧醫院有限公司),
 C w
 20, 2015, C , -w w
 C ., . (青田康寧醫院有限公司),
 C w A 1,
 2011, C , w w
 B w C
 () () C , w
 B1.00 , D ()
 () () ()
 (深圳怡寧醫院, w
 C ., . (深圳怡寧醫院有限公司),
 C ., . (深圳市怡寧醫院有限公司)),
 C w
 22, 2014, C , -w w
 (C 622 w) C

C C C ., . (溫州慈寧醫院有限公司),
C w 25,
2006, C ' w w

老年醫院有限公司), (溫州甌海怡寧
8, 2021, -w C w
C

() C ., . (怡寧心
理互聯網醫院(溫州)有限公司), C
w 10, 2020, C